Development of a model for predicting the severity of chronic obstructive pulmonary disease

被引:2
|
作者
Gu, Yu-Feng [1 ]
Chen, Long [2 ]
Qiu, Rong [3 ]
Wang, Shu-Hong [3 ]
Chen, Ping [4 ]
机构
[1] Suining Cent Hosp, Dept Informat, Suining, Peoples R China
[2] Suining Cent Hosp, Dept Res Management, Suining, Peoples R China
[3] Suining Cent Hosp, Dept Resp & Crit Care Med, Suining, Peoples R China
[4] Suining Cent Hosp, Dept Nerve Cent, Suining, Peoples R China
关键词
chronic obstructive pulmonary disease; prediction model; severity; retrospective study; biochemical and immunological; PLATELET-ACTIVATING-FACTOR; PLASMA-FIBRINOGEN; INCREASED RISK; COPD SEVERITY; EXACERBATIONS; EXPRESSION; MORTALITY; BLOOD; LIFE;
D O I
10.3389/fmed.2022.1073536
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundSeveral models have been developed to predict the severity and prognosis of chronic obstructive pulmonary disease (COPD). This study aimed to identify potential predictors and construct a prediction model for COPD severity using biochemical and immunological parameters. MethodsA total of 6,274 patients with COPD were recruited between July 2010 and July 2018. COPD severity was classified into mild, moderate, severe, and very severe based on the Global Initiative for Chronic Obstructive Lung Disease guidelines. A multivariate logistic regression model was constructed to identify predictors of COPD severity. The predictive ability of the model was assessed by measuring sensitivity, specificity, accuracy, and concordance. ResultsOf 6,274 COPD patients, 2,644, 2,600, and 1,030 had mild/moderate, severe, and very severe disease, respectively. The factors that could distinguish between mild/moderate and severe cases were vascular disorders (OR: 1.44; P < 0.001), high-density lipoprotein (HDL) (OR: 1.83; P < 0.001), plasma fibrinogen (OR: 1.08; P = 0.002), fructosamine (OR: 1.12; P = 0.002), standard bicarbonate concentration (OR: 1.09; P < 0.001), partial pressure of carbon dioxide (OR: 1.09; P < 0.001), age (OR: 0.97; P < 0.001), eosinophil count (OR: 0.66; P = 0.042), lymphocyte ratio (OR: 0.97; P < 0.001), and apolipoprotein A1 (OR: 0.56; P = 0.003). The factors that could distinguish between mild/moderate and very severe cases were vascular disorders (OR: 1.59; P < 0.001), HDL (OR: 2.54; P < 0.001), plasma fibrinogen (OR: 1.10; P = 0.012), fructosamine (OR: 1.18; P = 0.001), partial pressure of oxygen (OR: 1.00; P = 0.007), plasma carbon dioxide concentration (OR: 1.01; P < 0.001), standard bicarbonate concentration (OR: 1.13; P < 0.001), partial pressure of carbon dioxide (OR: 1.16; P < 0.001), age (OR: 0.91; P < 0.001), sex (OR: 0.71; P = 0.010), allergic diseases (OR: 0.51; P = 0.009), eosinophil count (OR: 0.42; P = 0.014), lymphocyte ratio (OR: 0.93; P < 0.001), and apolipoprotein A1 (OR: 0.45; P = 0.005). The prediction model correctly predicted disease severity in 60.17% of patients, and kappa coefficient was 0.35 (95% CI: 0.33-0.37). ConclusionThis study developed a prediction model for COPD severity based on biochemical and immunological parameters, which should be validated in additional cohorts.
引用
收藏
页数:10
相关论文
共 50 条
  • [22] Factors affecting the severity of fatigue in male patients with chronic obstructive pulmonary disease
    Alpaydin, A. O.
    Aktan, R.
    Keles, E.
    Ozalevli, S.
    REVISTA CLINICA ESPANOLA, 2021, 221 (02): : 86 - 92
  • [23] Peripheral T Cell Functions Correlate with the Severity of Chronic Obstructive Pulmonary Disease
    Zhu, Xuehai
    Gadgil, Aneal S.
    Givelber, Rachel
    George, M. Patricia
    Stoner, Michael W.
    Sciurba, Frank C.
    Duncan, Steven R.
    JOURNAL OF IMMUNOLOGY, 2009, 182 (05) : 3270 - 3277
  • [24] Chronic Obstructive Pulmonary Disease Biomarkers and Their Interpretation
    Stockley, Robert A.
    Halpin, David M. G.
    Celli, Bartolome R.
    Singh, Dave
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199 (10) : 1195 - 1204
  • [25] Validation of the Rome proposal for severity of acute exacerbation of chronic obstructive pulmonary disease
    Lee, Hyo Jin
    Lee, Jung-Kyu
    Park, Tae Yun
    Heo, Eun Young
    Kim, Deog Kyeom
    Lee, Hyun Woo
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2023, 17
  • [26] Macrolides for macrophages in chronic obstructive pulmonary disease
    Hansbro, Philip M.
    Jarnicki, Andrew G.
    RESPIROLOGY, 2012, 17 (05) : 739 - 740
  • [27] Chronic obstructive pulmonary disease
    Vijayan, V. K.
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2013, 137 : 251 - 269
  • [28] in Chronic Obstructive Pulmonary Disease
    Huang, Siyuan
    Feng, Tao
    Wang, Jing
    Dong, Liang
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2022, 17 : 1339 - 1347
  • [29] Depression in Patients with Chronic Obstructive Pulmonary Disease
    Garvey, Christine
    POSTGRADUATE MEDICINE, 2012, 124 (03) : 101 - 109
  • [30] A Patient Charter for Chronic Obstructive Pulmonary Disease
    Hurst, John R.
    Winders, Tonya
    Worth, Heinrich
    Bhutani, Mohit
    Gruffydd-Jones, Kevin
    Stolz, Daiana
    Dransfield, Mark T.
    ADVANCES IN THERAPY, 2021, 38 (01) : 11 - 23